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saveat Emptor
he Coronary Calcium Warranty
in et al. (1) provide welcome evidence that coronary artery
alcium (CAC) conversion from zero to a positive score occurs at
ow frequency before 4 years. They note that this finding applies to
middle-age, low- to intermediate-risk individuals,” in whom a
ero score is common. They are to be congratulated for the low
ose of radiation per scan (0.5 mSV).
Although readers are cautioned that repeat CAC testing has not
een formally recommended in any guideline to date, they may ask
ow to specifically apply these results to the population for whom
urrent guidelines endorse baseline CAC testing (2). The mean
ramingham risk score of the Min et al. (1) CAC  0 cohort was
%, placing many of the subjects in the low-risk group by National
holesterol Education Program guidelines (2). CAC scoring is not
urrently endorsed for patients at low risk (Framingham risk score
10%), as opposed to those at intermediate risk (Framingham risk
core, 10% to 20%), who may benefit from risk reclassification (2).
hus, the investigators’ recommended warranty period of 4 years
ay be too long when applied to classically intermediate-risk
atients undergoing CAC testing.
It would be beneficial for clinicians to have the “warranty
eriod” stratified by baseline risk group (10% and 10% to 20%).
t may even be prudent to stratify further, as some have advocated
or CAC testing in an expanded intermediate-risk group of 6% to
0% (e.g., 6%, 6% to 10%, and 10% to 20%) (3).
The finding that many traditional risk factors were not associ-
ted with the progression of CAC to a higher score in the baseline
AC 0 group is likely a function of the short duration of
ollow-up (1.9 years) and the definition of CAC progression in this
roup as “any increase in CAC score.” Progression results in this
roup may have been from interscan variability alone and not from
isease progression. Perhaps the investigators could have mini-
ized the effect of variability by incorporating a more specific and
linically meaningful cutoff (such as a 15% relative change
etween scans [4]).
The investigators may also have been overly prudent to suggest
hat “caution should be applied to interpreting our results among
atients who are not receiving lipid-lowering therapy.” Although
hey express concern that the 756 patients on statin therapy (72%)
ay have had retarded CAC progression, randomized trials to date
ave not shown that statin therapy can achieve this (5–6).
CAC  0 has enormous potential for ruling out important
oronary artery disease in asymptomatic patients. The duration and
pplication of the “warranty period” remains an important topic for
urther research.
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e thank Dr. McEvoy and colleagues for their interest in our
tudy (1). They raise several pertinent points that deserve response.
s noted, the mean 10-year coronary heart disease (CHD)
ramingham risk score for our study cohort with coronary artery
alcium (CAC) scores of zero was 9%, which comprised 62%
ow-risk (10% 10-year risk), 34% intermediate-risk (10% to 20%
0-year risk), and 5% high-risk (20% 10-year risk) patients.
lthough CAC scoring is not presently endorsed for low-risk
atients, we observed relationships of CAC conversion and time to
onversion in low-risk versus intermediate-risk patients that merit
onsideration.
Time to conversion to CAC 0 in low-risk patients did not
iffer compared with intermediate-risk patients (4.01 vs. 4.17
ears, p  0.99), and low-risk patients even trended toward higher
ates of conversion from CAC  0 to CAC 0 (11% vs. 8%, p 
.08). These findings are in keeping with recent population-based
tudies of CAC, including the Multiethnic Study of Atheroscle-
osis, which demonstrated a prognostic value of CAC beyond the
